CRO

Executive Summary

Selvita (CRO) is a Poland-based contract research organization founded in 2007, specializing in drug discovery and development with a focus on oncology and immunology. The company bridges early discovery (target validation) to preclinical candidate nomination, offering integrated services including analytical, microbiology, and GMP/GLP-compliant development for small molecules, biologics, and other modalities. Headquartered in Krakow, Selvita has positioned itself as a cost-competitive yet high-quality partner for pharmaceutical and biotech companies seeking to outsource drug development activities. Its private status allows for operational flexibility and long-term strategic investments without quarterly earnings pressure. Selvita's growth trajectory is underpinned by the increasing global demand for outsourced R&D, particularly in specialized therapeutic areas. As a midsized CRO with deep expertise in oncology and immunology, it can capture niche projects that larger CROs may overlook. Key competitive advantages include a skilled scientific workforce in Poland, competitive pricing versus Western European and US peers, and a comprehensive service offering from discovery to early clinical support. The company is well-positioned to benefit from the trend of biopharma companies seeking diversified and cost-effective CRO partners. However, as a private entity, Selvita faces challenges in scaling client relationships and competing for large, global contracts, which are often awarded to larger CROs with broader geographic footprints.

Upcoming Catalysts (preview)

• Q3 2026Major Pharma Partnership or Contract Win50% success
• Q2 2026Expansion of Biologics and Advanced Modality Capabilities40% success
• TBDStrategic Acquisition or Equity Investment by Larger CRO30% success